Episode Details

Josh Mandel-Brehm, CEO of CAMP4 Therapeutics

In this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs).

Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously out of reach — particularly in rare genetic and CNS disorders.

We dive into:
— What makes CAMP4’s approach so different— How they’ve scaled in a challenging market— The transition from private to public— Building culture through rapid growth— What’s coming next in Syngap, urea cycle disorders, and more

Josh is sharp, mission-driven, and speaks with clarity on how to build a resilient biotech from the ground up.

This is one for anyone building bold platforms in biotech.